Nektar Therapeutics | NKTR - Debt


Nektar Therapeutics reported $0 in Debt for its fiscal quarter ending in June of 2022.





Debt Change Date
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
ALKERMES USD 1.58B 1.51B Mar/2026
Alterity Therapeutics Limited AUD 210.39K 120.67K Jun/2023
Amgen USD 57.32B 2.72B Mar/2026
Baxter International USD 9.69B 93M Mar/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 8.09B 1.53B Jun/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Cara Therapeutics USD 0 0 Mar/2025
Cipla INR 6.14B 1.76B Mar/2026
Dr.Reddys Laboratories INR 71.95B 5.39B Jun/2026
Eisai JPY 186.08B 50.58B Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
Exelixis USD 165.93M 3.61M Jun/2026
Gilead Sciences USD 22.17B 2.76B Mar/2026
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Grifols EUR 9.23B 626.05M Dec/2024
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Incyte USD 38.27M 1.16M Jun/2026
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
MacroGenics USD 36.51M 500K Mar/2026
Merck USD 49.12B 222M Mar/2026
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 49.01B 2.02B Jun/2026
Pfizer USD 63.19B 536M Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Takeda JPY 4.94T 58.13B Jun/2026
Teva Pharmaceutical Industries USD 16.91B 187M Mar/2026
Xencor USD 175.16M 12.58M Mar/2026